| Literature DB >> 33394059 |
Julian Hoevelmann1, Felix Mahfoud2, Lucas Lauder2, Bruno Scheller2, Michael Böhm2, Sebastian Ewen2.
Abstract
Valvular heart disease (VHD) is common in patients with impaired renal function, especially in those with end-stage renal disease (ESRD) undergoing dialysis. Progressive sclerosis and calcification of the valves and valvular annuli are major components of the etiology. These processes typically affect the aortic and mitral valve and can lead to both valvular insufficiency and stenosis. As recommended by the 2017 ESC/EACTS Guidelines for the management of VHD, surgical treatment remains the standard care for most cases of severe VHD. However, chronic kidney disease (CKD) is associated with increased mortality when compared with patients with preserved renal function. Interventional treatment options have emerged as an effective and safe alternative for patients older than 75 years and/or with increased surgical risk. Consequently, in patients with CKD at increased surgical risk who have suitable anatomical morphology, transcatheter replacement and/or repair should be discussed in the interdisciplinary "heart team."Entities:
Keywords: Cardiovascular disease; Interventional treatment options; MitraClipTM; Renal insufficiency, chronic; Transcatheter aortic valve replacement
Year: 2021 PMID: 33394059 DOI: 10.1007/s00059-020-05011-0
Source DB: PubMed Journal: Herz ISSN: 0340-9937 Impact factor: 1.443